There are currently 442 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT04725383
Recruiting
The investigators will recruit 30 children and adolescents (15 per group x 2 groups) aged 6 to 17 years with ASD and significant repetitive behaviors that cause problems to them and to others around them. Subjects will be randomized to either amitriptyline (AMI), dosed flexibly according to response and tolerability with a maximum dose of 100mg per day or 1.5mg/kg/day, in divided doses to minimize side effects, or placebo in look-alike capsules, for 10 weeks. Rating scales will be used to measur... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
11/02/2023
Locations: University Health Behavioral Health Canvas Building, Kansas City, Missouri
Conditions: Autism Spectrum Disorder, Repetitive Compulsive Behavior
Register for Updates
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
NCT04467801
Recruiting
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: The University of Kansas Cancer Center, North Clinic, Kansas City, Missouri
Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 5, Kansas City, Missouri
Conditions: FSGS
Register for Updates
Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment
NCT06067607
Recruiting
The goal of this study is to learn about eye gaze technology's use as an assessment and intervention of visual skills and the impact on occupational performance in children with cortical/cerebral visual impairment. The main questions the study aims to answer are: * Does the use of eye gaze technology with graded visual activities improve visual abilities: * Does an improvement in visual abilities improve occupational performance? - What are the factors that correlate with improved visual abilit... Read More
Gender:
ALL
Ages:
Between 2 years and 10 years
Trial Updated:
10/02/2023
Locations: The Children's Center for the Visually Impaired, Kansas City, Missouri
Conditions: Cortical/Cerebral Visual Impairment, Cerebral Palsy
Register for Updates
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Alliance for Multispecialty Research, LLC, Kansas City, Missouri
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - North Kansas City Hospital, Kansas City, Missouri +1 locations
Conditions: Breast Cancer
Register for Updates
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02302742
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2023
Locations: Truman Medical Center, Kansas City, Missouri +3 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Register for Updates
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
NCT00574327
Recruiting
The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of GERD and BE patients and risk factors for development of BE in patients with chronic GERD and progression of BE to dysplasia and adenocarcinoma will provide useful information to develop a decision mod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2023
Locations: Department of Veterans Affairs Medical Center, Kansas City, Missouri
Conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Kansas City VA Medical Center, Kansas City, Missouri
Conditions: End Stage Liver Disease
Register for Updates
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04816578
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: Midamerica Cancer Care, Kansas City, Missouri
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Register for Updates